Chemomab Therapeutics Ltd. (2QV)

Overview

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Founded in 2011 and based in Tel Aviv, Israel, the company seeks to address significant unmet medical needs in the field of fibrosis and inflammation. Operating primarily in the United States, Chemomab leverages cutting-edge scientific research and development to advance its pipeline of novel treatment options for patients suffering from these serious conditions.

Products and Services

• CM-101

CM-101 is Chemomab Therapeutics Ltd.’s lead product candidate. It is a humanized monoclonal antibody designed to target and attenuate the basic function of CCL24, a chemokine known to play a significant role in the pathogenesis of various fibrotic and inflammatory diseases. CM-101 is currently undergoing phase 2 clinical trials, focusing on two main indications:

• Primary Sclerosing Cholangitis (PSC): A rare, chronic, and progressive disease of the bile ducts that leads to liver damage. CM-101 aims to provide a much-needed treatment option for managing this condition by mitigating inflammatory responses associated with PSC.
• Systemic Sclerosis (SSc): Also known as scleroderma, SSc is a multisystem autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. Through its action on CCL24, CM-101 seeks to offer a novel approach to treating the fibrotic and inflammatory aspects of SSc.